TELIK Inc. - 500 Beiträge pro Seite

[Kostolanys Erbe]

Hallo Leute,

habe mich mal mit diesem Wert beschäftigt. Ich denke, das jeder sich mal die homepage besuchen sollte. Dort gibt es wirklich sehr interessante Info`s.


Clinical Trials Phase Study Site(s)
TLK286 Dose Escalation Study in Patients with Advanced Malignancies Phase 1 University of California, Los Angeles

TLK286 in Patients with Platinum-Resistant, Non-Small Cell Lung Cancer Phase 2 University of California, Los Angeles
Arizona Cancer Center
M.D. Anderson Cancer Center

TLK286 in Platinum-Resistant Ovarian Cancer Phase 2 M.D. Anderson Cancer Center
Memorial Sloan-Kettering Cancer Center
Fox Chase Cancer Center

TLK286 in Patients with Colorectal Cancer Phase 2 University of California, Los Angeles
University of Southern California
M.D. Anderson Cancer Center
Arizona Cancer Center
Oregon Health Sciences University

www.Telik.com

wirklich sehr informativ.

Kosto

Was meint ihr?

[puhvogel]

Ein hochinteressanter Wert!
Wenn Du eine gute Analyse (keine Angst, ist nicht von mir ) haben möchtest, dann gib mir eine mail-Adresse auf die Postbox durch.

[Kostolanys Erbe]

Hallo puhvogel,

hast du meine adresse per postbox erhalten?

Schön das sich auch jemand für diesen Wert interessiert. Habe Telik Inc. schon länger im Visier, bin mir aber noch unschlüssig. Habe aber in diesem Board noch keine Informationen über diesen Wert erhalten. Wäre schön, wenn man dies hier zusammentragen könnte.

Telik (Nasdaq: *!TELK!*) - BUY - Telik, based in San Francisco, CA, is a
biotechnology company with expertise in identifying and developing small
molecule drugs. The company`s core TRAP technology, a novel "low
throughput" approach for drug screening, complements traditional high
throughput methods.

Strengths:
* Strong cash position. As of the end of 2Q01, Telik had $36.2 million
in cash and equivalents. The company recently completed a secondary
offering, further strengthening its cash position. While the burn rate
will increase as the clinical development program expands, Telik has
ample cash reserves.

* Fully owned clinical and late development candidates. Telik has
complete ownership of its two most advanced candidates, TLK-286 and
TLK-199 and is conducting its own clinical trial programs for these
drugs, maximizing the value of these candidates.

* Low visibility, high potential early pipeline. TLK-286 is Telik`s only
product currently in clinical testing. However, phase I trials for
candidate TLK-199, a drug that mimics the effect of Neupogen (Amgen),
which had 2000 sales of $1.2 billion are expected to begin by year-end.
Also in preclinical development is TLK-17411, a promising treatment for
diabetes.


Was meinst du puhvogel?

[Kostolanys Erbe]

puhvogel----vielen dank für deine mail!!!
neue infos:

January 7, 2002
Telik Announces Clinical Progress with TLK286 and Plans for Initiation of Phase 2 Trial in Breast Cancer

COMPANY OVERVIEW
Telik, Inc. (Nasdaq: TELK) is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs focused in cancer and diabetes. The company`s most advanced drug development programs include: TLK286, a tumor activated drug candidate currently in Phase 2 clinical trials for the treatment of chemotherapy resistant colorectal, ovarian and non-small cell lung cancers; TLK199, a candidate for the treatment of depletion of infection-fighting white blood cells that occurs as a toxic side effect of cancer therapy as well as in other blood diseases such as myelodysplastic syndrome; and a family of orally active insulin receptor activators for Type 2 diabetes. Telik`s product candidates were discovered using its proprietary technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.

Our strategy for maximizing the commercial value of our product pipeline is to retain rights through initial clinical safety and efficacy evaluations. Once we have demonstrated clinical utility, we will evaluate a range of development and commercialization options.

In addition to its proprietary drug development programs, Telik partners with pharmaceutical and biotechnology companies to apply its TRAP technology to a variety of research programs directed at new drug development. Current partners include Sanwa Kagaku Kenkyuosho Co., Ltd. and Sankyo Company, Ltd. Telik also collaborates with leading academic institutions including the University of Arizona Cancer Center, the University of California, San Francisco and the Fox Chase Cancer Center.



TELIK, INC.
750 GATEWAY BLVD., SOUTH SAN FRANCISCO, CALIFORNIA 94080
TEL: [phone] • FAX: [phone]

[Kostolanys Erbe]

Telik heute gegen den Trend nach oben!


neue news:

Telik Announces Webcast of Presentation At Wachovia Securities Integrated Oncology Conference

SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Jan. 14, 2002-- Telik, Inc. (Nasdaq: TELK) today announced that Michael M. Wick, M.D., Ph.D., Telik`s Chairman and Chief Executive Officer, will present at the Wachovia Securities Integrated Oncology Conference at the St Regis Hotel in New York on Wednesday, January 16, 2002 at 8:00 a.m. Eastern time.

The audio webcast will be available on Telik`s website at http://www.telik.com through Friday, January 25, 2002.

Telik, Inc. of South San Francisco, California, is a biopharmaceutical company working to discover, develop, and commercialize small molecule drugs to treat serious diseases for which there is significant demand for new therapies. Telik`s product candidates were discovered using its proprietary technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.

Telik, Inc. TELK
Jan. 14, 2002 Market Closed

Last Sale: $ 13.30 Net Change: 0.35 2.7% Web Site
Latest News
Today`s High: $ 13.30 Today`s Low: $ 12.50
Best Bid: $ 13.29 Best Ask: $ 13.30
Volume: 243,300 Previous Close: $ 12.95
Market: Nasdaq-NM Common Stock


Charttechnisch sieht es bei Telik zur Zeit nach einer W-Formation aus! Bis Mittwoch den 16.01.02 !!!

Kosto

[Kostolanys Erbe]

Bei Telik war der Freitag nicht so erfreulich. Obwohl es keine neuen news gab, fiel Telik bei schwachen Gesamtmarkt.

Telik, Inc. TELK
Jan. 18, 2002 Market Closed

Last Sale: $ 11.88 Net Change: 0.82 6.46% Analyst Forecast Change
Web Site

Today`s High: $ 12.59 Today`s Low: $ 11.55
Best Bid: $ 11.87 Best Ask: $ 12.09
Volume: 177,700 Previous Close: $ 12.70
Market: Nasdaq-NM Common Stock

Aus meiner Sicht ein sehr interessanter Wert.
Stelle gerne die Informationen von Puhvogel zur Verfügung.
Also, wer Interesse hat, kann sich ja bei mir melden.

Kosto